PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

Inc., a leading provider of software solutions for product design, manufacturing, and service, continues to navigate a challenging macroeconomic environment while positioning itself for future growth.

PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...

PTC's fiscal first-quarter performance is likely to have been driven by demand for PLM and CAD in a tough selling environment and go-to-market realignment.

The stock's fall snapped a two-day winning streak.

Barclays analyst Saket Kalia maintained a Buy rating on PTC (PTC – Research Report) today and set a price target of $215.00. The company’s ...

Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $113 from $76 and keeps an Overweight rating on the shares. PTC ...

The Delhi Police on Tuesday filed two cases related to alleged violations of the Model Code of Conduct (MCC) ahead of the ...

With both sides showing no signs of backing down, the renewed trade war threatens to further disrupt global supply chains and ...

One of the top advanced manufacturing and material technology companies, PTC Industries, has inked a Memorandum of ...

PTC Industries inks aerospace MoU with Odisha government, sparking a nearly 5% rally in the company’s stock price.

PTC automatically controls train speeds when needed, reducing the risk of train collisions and preventing human error, while ...